Neoplasms Clinical Trial
Official title:
One-arm Exploratory Study on the Efficacy and Safety of Apatinib Combined With SHR-1210 Injection (PD-1 Antibody) in the Treatment of Removable IB-IIIA Non-small Cell Lung Cancer
The aim of this study was to investigate the safety and efficacy of SHR-1210 in combination with the anti-vascular survival target drug apatinib in patients with resectable NSCLC, and to provide new treatment options for neoadjuvant therapy in patients with the period IB-IIIA NSCLC.
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | June 2021 |
Est. primary completion date | June 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - 1. Age: 18 years old to 75 years old, male or female; - 2. Initial treatment of patients with IB-IIIA non-small cell lung cancer who are expected to be surgically resected; - 3. Histopathologically confirmed non-small cell lung cancer with measurable tumor lesions (spiral CT scan=10mm, meeting RECIST 1.1 criteria); - 4. ECOG PS: 0-1 points - 5. The function of important organs meets the following requirements (no blood components and cell growth factors are allowed for 2 weeks before the start of study): Absolute neutrophil count (ANC)=1.5×10 E+9/L; platelets=100×10E+9/L / L; hemoglobin =9g/dL; serum albumin(ALB)=2.8g/dL; a total bilirubin (TBil) of=1.5 ULN, ALT and AST=2.5 ULN, in case of liver metastasis, ALT and AST=5 ULN; creatinine clearance rate= 50mL/min(Cockcroft-Gault);thyroid function is normal. - 6. Estimated survival time=3 months; - 7. Female subjects with fertility should undergo a urine or serum pregnancy test within 72 hours prior to the first study drug administration and are shown to be negative ,and willing to be 3 months after the last dose of SHR-1210 injection during the trial period. The effective method was used for contraception (from the control group to 180 days after the last administration). For male subjects whose partners are women of childbearing age, effective methods should be used during the test period and within 3 months after the last administration of SHR-1210 injection (control group to 180 days after the last administration); - 8. Patients were voluntarily enrolled in the study and signed an informed consent form (ICF) with good adherence and follow-up. Exclusion Criteria: - 1. The patient has any active autoimmune disease or a history of autoimmune disease; - 2.The patient is using immunosuppressive agents or systemic hormonal therapy for immunosuppression purposes (dose>10 mg / day of prednisone or other therapeutic hormones); - 3.Interstitial pneumonia ; - 4.Severe allergic reactions to other monoclonal antibodies ; - 5.Suffering from high blood pressure and not being well controlled by antihypertensive medication (systolic blood pressure=140 mmHg or diastolic blood pressure=90 mmHg) ; - 6.Have clinical symptoms or disease that are not well controlled ; - 7.Abnormal coagulation function (INR>2.0, PT>16s), bleeding tendency or receiving thrombolysis or anticoagulant therapy, allowing prophylactic use of low-dose aspirin, low molecular weight heparin; - 8.There was significant coughing blood in the first 2 months before enrollment, or daily hemoptysis amounted to 2.5ml or more; - 9.Significant clinically significant bleeding symptoms or a clear tendency to hemorrhage during the first 3 months of randomization; - 10.Urinary routine suggests urinary protein= ++ and confirmed 24-hour urine protein> 1.0 g ; - 11.The patient has active infection, unexplained fever within 3 days before administration, =38.5 °C, or baseline white blood cell count>15×109/L; - 12.The patient has previously received other PD-1 antibody therapy or other immunotherapy against PD-1/PD-L1; - 13.Other patients considered by the treating physician not suitable for inclusion . |
Country | Name | City | State |
---|---|---|---|
China | Sichuan Cancer Hospital | Chengdu | Sichuan |
Lead Sponsor | Collaborator |
---|---|
Sichuan Cancer Hospital and Research Institute | Jiangsu HengRui Medicine Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Incidence of irAEs | Grade 3 or higher per Common Terminology Criteria for Adverse Events (CTCAE V5.0) | up to 2 years | |
Other | Incidence of SAEs | Grade 3 or higher per Common Terminology Criteria for Adverse Events (CTCAE V5.0) | up to 2 years | |
Primary | Major pathologic response rate(MPR)(<10% viable tumor cells) | To assess the major pathologic response rate (<10% viable tumor cells) in patients receiving Apatinib Combined With SHR-1210 Injection. | At time of surgery | |
Secondary | Disease Control Rate (DCR) | the proportion of patients with a best overall response of CR, PR or SD in the whole body, as assessed per RECIST 1.1 by the investigator. | up to 2 years | |
Secondary | Overall response rate (ORR) | the proportion of patients with a best overall confirmed response of CR or PR in the whole body as assessed per RECIST 1.1 by the investigator | up to 2 years | |
Secondary | Disease-free survival (DFS) | Defined as the time from date of surgery until recurrence of tumor or death from any cause | up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
Completed |
NCT02909348 -
Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab
|